Company History
Founded in 1998, Pharmaxis was listed on the Australian Stock Exchange in 2003 (symbol PXS), and on the NASDAQ (symbol PXSL) in 2005.
Headquartered in Sydney at its TGA-approved manufacturing facilities, Pharmaxis has grown to become among Australia’s largest life sciences companies, with offices in the US, UK and China.
A new 7,000 square metre factory and headquarters is under construction in Frenchs Forest, Sydney, in preparation for the launch of Bronchitol to overseas markets.
Milestones
2008 (to date)
- Bronchitol cystic fibrosis dose trial results positive
- 1st global Phase 3 cystic fibrosis trial completes enrollment
- 2nd global Phase 3 cystic fibrosis trial commences enrolment
- Cystic fibrosis trial in children returns positive results with Bronchitol
- 1st Phase 3 bronchiectasis trial reports positive long term safety data
- 1st marketing application filed for Bronchitol with Australian TGA
- Construction begins on new factory and headquarters in Frenchs Forest
- Aridol gains approval in Korea
- Aridol available throughout major European countries
- US FDA meeting confirms Aridol marketing submission plans
- Aridol for elite athletes accepted by Olympic Committee
2007
- Successful completion of $50 million capital raising and share purchase plan
- EU approval of Aridol — 13 European countries to market
- Phase III Bronchitol trial completes with positive results
- Phase II clinical trial demonstrates role for Aridol in COPD
- European headquarters established in UK
2006
- Aridol approved for sale and marketing in Sweden and Australia
- First European distributors appointed
- European Medicines Agency grants Bronchitol Orphan Drug status for cystic fibrosis
- U.S. Aridol Phase III trial involving 500 patients concluded successfully
- Completed global capital raising of $87 million on ASX and NASDAQ — the largest of any Australian pharmaceutical company
2005
- Tripled manufacturing capacity
- US FDA grants Bronchitol Orphan Drug status for bronchiectasis and cystic fibrosis
- NASDAQ Global Market listing of Pharmaxis
2004
- Aridol Phase III and Bronchitol Phase II clinical trials completed
- Capital raising of $19.8 million
- Awarded $6.1 million AusIndustry P3 Grant
2003
- Listed on Australian Securities Exchange, Initial Public Offering raised $25 million
- Manufacturing facility licensed by TGA; production begins
- Awarded $6 million AusIndustry R&D Start Grant to develop new cystic fibrosis treatments
2002
- Completed Series B private funding of $9.6m
- Frenchs Forest facility established
2001
- Pharmaxis licenses patents for respiratory products from technology developed by Royal Prince Alfred Hospital, Sydney
